Serodus is a private Scandinavian drug development company with a pipeline focusing on novel, immuno-modulators stopping progression of diabetic kidney desease.
Lead candidate SER150 targets Diabetic Kidney Disease, representing an attractive market and significant recognized unmet medical need. SER150 showed positive phase 2a development results. A confirmatory clinical study is expected to start during 2021-H1.
All currently available treatments for T2D are initially effective in reducing blood glucose and reduce complication rates, but they lack the ability to stop the systemic inflammation driving the pathophysiological processes of diabetes and its complications.
Our candidates target the fundamental underlying systemic inflammation causing diabetes and its comorbidities.
Company Details
- Founded
- -
- Address
- C/o Arnstein Endresen, Heia 8,norway
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- serodus.com
- Keywords
- for Renewable Energy.
- HQ
- OSLO, Oslo
Serodus As (Ser) Questions
Serodus As (Ser)'s website is serodus.com
Serodus As (Ser)'s LinkedIn profile is https://no.linkedin.com/company/serodus-as
Serodus As (Ser)'s industry is
Pharmaceutical Manufacturing
Serodus As (Ser)'s top competitors are
Philaflor,
Varmstrøm,
Eagle Farming Brits,
Bepro,
Spraino,
Peak Element Aps,
Ray Earplugs,
Astro Energia,
Marhaz Aps,
Saim Medical.
Serodus As (Ser)'s categories are Pharmaceutical Manufacturing
Serodus As (Ser)'s founding year is 2008
